Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Google Cloud's updated its Vertex AI platform to support AI agents with including the Agent Development Kit, the Agent2Agent ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

BNP Paribas Exane initiated coverage of Vertex (VERX) with an Outperform rating and $54 price target Stay Ahead of the Market: Discover ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.3, a high estimate of $61.00, and a low estimate of $31.00. A 14.64% drop is evident in the current ...

For the full year 2025, Vertex (NASDAQ:VRTX) projects revenue to be in the range of $11.75 billion to $12 billion. In recent developments, Vertex announced that the United Kingdom Medicines and ...

DA Davidson lowered the firm’s price target on Vertex (VERX) to $50 from $55 and keeps a Buy rating on the shares as part of a broader research note updating estimates within the firm’s coverage of ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy ... been insulin-independent for four years with normal-range HbA1c levels, according to a recent company ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily ...

TechTarget, Inc. (Nasdaq: TTGT), (“Informa TechTarget” or the “Company”), a leading growth accelerator for the B2B Technology sector, today re-confirms its revenue range for 2024 ...

The USN lists the F/A-18E/F's range in combat configuration as 1,275 n miles (2,346 km), meaning that F/A-XX will likely be required to fly at least 1,500 n miles (2,950 km) unrefuelled.